{"id":9040,"date":"2026-04-16T10:56:01","date_gmt":"2026-04-16T08:56:01","guid":{"rendered":"https:\/\/inoc.it\/clinical-trials\/"},"modified":"2026-07-30T10:34:56","modified_gmt":"2026-07-30T08:34:56","slug":"clinical-trials","status":"publish","type":"page","link":"https:\/\/inoc.it\/en\/clinical-trials\/","title":{"rendered":"Clinical Trials"},"content":{"rendered":"\n

INOC is currently conducting over 200 clinical trials<\/strong> registered on international platforms<\/strong>, ranging from interventional studies\u2014across various stages of drug development\u2014to nursing and surgical studies. Among the areas of greatest innovation are: cell therapies and CAR-T therapies, cancer vaccines, oncolytic viruses, bispecific antibodies, antibody-drug conjugates, and molecularly targeted therapies. <\/p>\n\n

To support this research, INOC\u2019s advanced molecular diagnostics service<\/strong> is capable, for certain clinical cases, of analyzing over 500 genetic variants<\/strong> associated with more than 28 types of cancer, enabling precise guidance in treatment selection and facilitating access to targeted clinical trials.<\/p>\n\n

Use the search engine to find active clinical trials<\/strong> and see if there are any opportunities to participate that are suitable for your medical condition.<\/p>\n\t

\n\t\t\t\n\n
<\/div>\n\n\t<\/div>\n\n
\n
\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
\n
\n
\n
<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n\n\n\t
\n\t\t\n\n
<\/div>\n\n\t<\/div>\n\n\n\n
1456-0001<\/a><\/div>
A study to evaluate different doses of BI 18 31169, either alone or in combination with an anti-PD-1 antibody, in people with various types of advanced cancer (solid tumors).<\/div>
Diseases: Gastrointestinal tumor (GI tumor)<\/span>, Head and neck cancers<\/span>, Melanoma<\/span>, Pancreatic cancer<\/span><\/div>
Medication: BI 1831169 (VSV-GP)\r\nBI 754091 (Ezabenlimab; anti-PD-1 mAb)<\/div>
FASE I<\/span><\/div><\/div><\/div><\/div>
8951-0305<\/a><\/div>
A Phase 3, Double-Blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) for the first-line treatment of locally advanced, unresectable, or metastatic gastric or gastroesophageal adenocarcinoma in participants whose tumors are HER2-negative, Claudin (CLDN) 18.2-positive, and whose combined positive scores (CPS) are greater than or equal to 1.<\/div>
Diseases: Gastrointestinal tumor (GI tumor)<\/span><\/div>
Medication: Zolbetuximab in combination with pembrolizumab + (CAPOX or mFOLFOX6) <\/div>
FASE III<\/span><\/div><\/div><\/div><\/div>
AndroMETa-Lung-713 M25-713<\/a><\/div>
A Phase 2\/3, open-label, randomized study of telisotuzumab adizutecan compared with standard of care in patients with locally advanced or metastatic non-squamous non-small cell lung cancer with an EGFR mutation, following progression on a third-generation TKI.<\/div>
Diseases: Lung Cancer<\/span><\/div>
Medication: Osimertinib \n, Telisotuzumab Adizutecan <\/div>
FASE II<\/span><\/div><\/div><\/div><\/div>
Artemide Lung 04 - D702GC00001<\/a><\/div>
A global, randomized, double-blind, multicenter Phase III study of Rilvegostomig or Pembrolizumab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (D702BC00001).<\/div>
Diseases: Lung Cancer<\/span><\/div>
Medication: Rilvegostomig \n, Pembrolizumab<\/div>
FASE III<\/span><\/div><\/div><\/div><\/div>
AxIn<\/a><\/div>
A Phase II study comparing the intensification of axitinib in combination with nivolumab versus nivolumab alone following induction therapy with nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma (mRCC) who have not previously achieved a complete response.<\/div>
Diseases: Kidney cancer (renal cancer)<\/span><\/div>
Medication: Axitinib in combination with nivolumab or nivolumab alone <\/div>
FASE II<\/span><\/div><\/div><\/div><\/div>
Beamion BCGC-1<\/a><\/div>
A multicenter, randomized, open-label, Phase Ib dose-escalation and Phase II dose-optimization study of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2-positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC).<\/div>
Diseases: Breast Cancer<\/span>, Gastrointestinal tumor (GI tumor)<\/span><\/div>
Medication: Oral zongertinib (BI 1810631) alone or in combination with other standard therapeutic agents.<\/div>
FASE II<\/span><\/div><\/div><\/div><\/div>
BL-B01D1-LUNG-101<\/a><\/div>
A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer.<\/div>
Diseases: Breast Cancer<\/span>, Male urologic cancers (urological tumors)<\/span><\/div>
Medication: BL-B01D1 (anti-EGFR and anti-HER3 antibody)<\/div>
FASE I<\/span><\/div><\/div><\/div><\/div>
BNT324-010<\/a><\/div>
A Phase Ib\/II, multicenter, open-label, two-part study to evaluate the efficacy, safety, pharmacokinetics, and recommended dose of the combination of BNT324 and BNT327 in participants with advanced lung cancer.<\/div>
Diseases: Lung Cancer<\/span><\/div>
Medication: BNT324 (antibody conjugate targeting B7-H3)\nBNT327 - Pumitamig (bispecific antibody for PD-L1 and VEGF-A)<\/div>
FASE II<\/span><\/div><\/div><\/div><\/div>
BNT324-03<\/a><\/div>
A Phase III, randomized, open-label study comparing BNT324 with docetaxel plus prednisone\/prednisolone in patients with castration-resistant metastatic prostate cancer.<\/div>
Diseases: Male urologic cancers (urological tumors)<\/span><\/div>
Medication: BNT324 vs. Docetaxel <\/div>
FASE III<\/span><\/div><\/div><\/div><\/div>
C6461013<\/a><\/div>
A Phase 1\/2a, open-label, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of combinations of BMS-986507 (BL-B01D1) in adult participants with advanced solid tumors.<\/div>
Diseases: <\/div>
Medication: PF-08634404 as monotherapy versus standard combination therapy.<\/div>
<\/div><\/div><\/div><\/div><\/div>\n